Roche warns U.S. drug pricing deals may raise Swiss launch prices

In an interview with Swiss newspaper Tages Anzeiger on December 20, 2025, Roche Chief Executive Thomas Schinecker warned that recent pricing accords between U.S. policymakers and drugmakers including Roche’s U.S. unit Genentech could have unintended consequences for Switzerland and other wealthy countries. The accords, announced the day before, require participating drugmakers to cut prices for medicines sold to the U.S. Medicaid program for low income people. Schinecker said the agreements “will likely push up the cost of new drugs in Switzerland.” He added that if Switzerland resisted raising launch prices to align with the new U.S. framework, “this would likely lead to further delays in introducing new medicines.”

Schinecker said Roche was in discussions with a group of developed nations that the United States is using as reference points in its pricing talks, naming Denmark, Germany, France, Britain, Italy, Japan, Canada and Switzerland. The decision to use reference pricing links price outcomes across markets, giving changes in U.S. reimbursement a direct channel to influence launch strategies and list prices in small, high income markets like Switzerland.

For pharmaceutical companies, the U.S. market accounts for an outsized share of global revenue. The combination of large sales volumes and relatively high U.S. prices has traditionally subsidized investment in drug development, and companies say changes to U.S. pricing dynamics force a reassessment of launch sequencing and pricing in countries with smaller patient pools. Industry executives argue that if list prices in benchmark countries are kept lower than a recalibrated U.S. price, manufacturers may raise Swiss launch prices to preserve global revenue or delay market entry while negotiating new terms.

Swiss political and media reaction has been swift, with lawmakers and public broadcasters characterizing the U.S. accords as new pressure on Switzerland’s pricing system. Policymakers will now face a choice between protecting lower domestic prices and risking slower access to newly developed medicines, or allowing higher launch prices that could increase public and private health spending.

Additional industry commentary has highlighted distribution and intermediary dynamics in the U.S. health system. Schinecker has criticized intermediaries, saying roughly half of money spent on drugs in the U.S. flows to pharmacy benefit managers rather than to developers, and Roche is reported to be exploring distribution strategies used by peers, including greater direct to consumer engagement, as a way to blunt intermediary costs.

From a policy perspective, the White House framed the accords as ensuring that other wealthy nations contribute more to funding innovation rather than relying on higher U.S. prices. The practical effect is likely to be a renewed focus on cross border price coordination, with regulators and payers in benchmark countries weighing the fiscal implications of any Swiss response.

For Swiss patients and payers the stakes are clear. A move toward higher launch prices would raise immediate budgetary pressures for insurers and the state. A strategy of resistance could result in delayed availability of new therapies. In the coming weeks health authorities in Switzerland, industry executives and U.S. policymakers will need to clarify how the accords translate into concrete price lists, timelines and safeguards for access.